US 8,580,858 B2 | Compositions for the treatment of CNS-related conditions

Please sign up or log in to access the advanced features of
Ex Parte Enterprise.

or Log in

General

US 8,580,858 B2

Compositions for the treatment of CNS-related conditions

Tech Center:

1600 Biotechnology and Organic Chemistry

Examiner:

Kendra D Carter

Art Unit:

1627 Organic Chemistry

Agent:

Scully, Scott, Murphy & Presser, P.C.

Inventors:

Gregory T. Went; Timothy J. Fultz; Laurence R. Meyerson

Assignee:

ADAMAS PHARMA, LLC

Priority:

11/23/04

Filed:

12/21/12

Granted:

11/12/13

Expiration:

11/23/24

Abstract

The invention provides compositions comprising extended release memantine in combination with immediate release donepezil to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt thereof in combination with donepezil achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.

General

Analytics

Cases

Patent Assignments

Citations